Advance of immunometabolomics in cardiovascular disease therapeutics: from mechanistic insights to clinical translation
10.12025/j.issn.1008-6358.2025.20250248
- VernacularTitle:免疫代谢组学在心血管疾病治疗中的研究进展：从机制到临床转化
- Author:
Lin MA
1
;
Shujuan LI
1
Author Information
1. Department of Emergency, The Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010000, Inner Mongolia, China.
- Publication Type:Review
- Keywords:
cardiovascular disease;
atherosclerosis;
metabolic reprogramming;
immunometabolomics;
artificial intelligence
- From:
Chinese Journal of Clinical Medicine
2025;32(6):1043-1052
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular disease (CVD) has emerged as one of the leading global causes of mortality, with their pathological progression closely linked to immune-metabolic dysregulation. Advances in immunometabolomics have unveiled the central role of metabolic reprogramming in cardiovascular injury. The metabolic reprogramming in immune cells critically regulates inflammatory responses, oxidative stress, and vascular remodeling, profoundly contributing to the pathogenesis of atherosclerosis, myocardial ischemia-reperfusion injury, and heart failure. The rapid development of immunometabolomic technologies has brought high-resolution dynamic mapping of metabolic-immune network interactions, driving the precise identification of metabolic targets and metabolites. Consequently, immune-metabolism-targeted intervention strategies exhibit promising therapeutic potential, particularly in modulating inflammatory microenvironment and improving cardiac metabolic homeostasis. Future efforts should integrate clinical translational research to develop personalized metabolic immunotherapies, offering novel directions for CVD prevention and treatment. This review synthesizes recent progress in immunometabolism research related to CVD, highlights advancements in immunometabolomic technologies, and outlines future therapeutic prospects for immune-metabolic interventions in CVD management.
